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ARTICLE
Standardizing CYP2D6 Genotype to Phenotype 
Translation: Consensus Recommendations from the 
Clinical Pharmacogenetics Implementation Consortium 
and Dutch Pharmacogenetics Working Group
Kelly E. Caudle1,*, Katrin Sangkuhl2, Michelle Whirl-Carrillo2, Jesse J. Swen3, Cyrine E. Haidar1, Teri E. Klein2, Roseann S. Gammal1,4, 
Mary V. Relling1, Stuart A. Scott5,6, Daniel L. Hertz7, Henk-Jan Guchelaar3 and Andrea Gaedigk8,9
Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacoge-
netic (PGx) testing and PGx clinical practice guidelines, such as the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) and the Dutch Pharmacogenetics Working Group (DPWG). The genotype to phenotype translation discordance between 
laboratories and guidelines can cause discordant cytochrome P450 2D6 (CYP2D6) phenotype assignments and, thus lead to 
inconsistent therapeutic recommendations and confusion among patients and clinicians. A modified-Delphi method was 
used to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of interna-
tional CYP2D6 experts. Experts with diverse involvement in CYP2D6 interpretation (clinicians, researchers, genetic testing 
laboratorians, and PGx implementers; n = 37) participated in conference calls and surveys. After completion of 7 surveys, 
a consensus (> 70%) was reached with 82% of the CYP2D6 experts agreeing to the final CYP2D6 genotype to phenotype 
translation method. Broad adoption of the proposed CYP2D6 genotype to phenotype translation method by guideline develop-
ers, such as CPIC and DPWG, and clinical laboratories as well as researchers will result in more consistent interpretation of 
CYP2D6 genotype.
Cytochrome P450 2D6 (CYP2D6) is directly involved in the 
metabolism of ~ 20% of currently approved medications,1 and 
genetic variation in the CYP2D6 gene has been implicated in 
the efficacy and/or toxicity of many drugs. Consequently, 
the highly polymorphic CYP2D6 gene is the focus of several 
Clinical Pharmacogenetics Implementation Consortium (CPIC) 
and/or Dutch Pharmacogenetics Working Group (DPWG) 
clinical practice guidelines on 15 widely used medications, 
including selective serotonin reuptake inhibitors, tricyclic anti-
depressants, atomoxetine, codeine, tramadol, tamoxifen, on-
dansetron, and tropisetron.2–8 Recently, the CPIC and DPWG 
reported some discrepancies in their guidelines, primarily 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Translating CYP2D6 genotype to metabolizer phenotype is 
not standardized across clinical laboratories offering pharma-
cogenetic (PGx) testing and PGx clinical practice guidelines.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  The purpose of this project was to harmonize the sys-
tems used by the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) and the Dutch Pharmacogenetics 
Working Group (DPWG) and reach consensus among an in-
ternational panel of CYP2D6 experts regarding the standard-
ization of how to translate CYP2D6 genotype to phenotype.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  We engaged a diverse group of international CYP2D6 
experts to establish a standardized method for translating 
CYP2D6 genotype to metabolizer phenotype.
HOW MIGHT THIS CHANGE CLINICAL PHARMA- 
COLOGY OR TRANSLATIONAL SCIENCE?
✔  Broad adoption of the proposed CYP2D6 genotype to 
phenotype translation method by guideline developers, 
such as the CPIC and DPWG, and clinical laboratories as 
well as researchers will result in more consistent interpre-
tation of CYP2D6 genotype.
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related to how certain CYP2D6 genotypes or diplotypes (from 
here on referred to as “genotype”) were translated into metab-
olizer phenotype or metabolizer status (from here on referred 
to as “phenotype”).9 Figure 1 describes the process used to 
translate identified CYP2D6 genetic variants into phenotypes. 
Given that the clinical recommendations for CYP2D6 in the 
CPIC and DPWG guidelines are based on phenotype, the as-
signment of CYP2D6 phenotype based on genotype is a criti-
cal aspect for consistent clinical implementation.
Translating CYP2D6 genotype to phenotype is also not 
standardized across clinical laboratories offering pharma-
cogenetic (PGx) testing. Current systems used to translate 
genotype to phenotype rely on the star (*) allele nomencla-
ture (defining which variant(s) are present in an allele), and 
the assignment of function to the star alleles (i.e., increased, 
normal, decreased, or no function) with inferring phenotype 
based on the identified genotype. Some systems utilize 
the activity score (AS) system for assignment of phenotype 
where each allele is assigned an “activity value” ranging from 
0−1 (e.g., 0 for no function, 0.5 for decreased function, and 
1.0 for normal function).10 In addition, given that the CYP2D6 
allele can also have variable copy number, the activity value 
of an allele is multiplied by the number of gene copies (i.e., 
×2, ×3, etc.) if copy number is known. If copy number is 
not known, a sample maybe defaulted to ×2 assignment or 
shown as xN. As such, the CYP2D6 AS is the sum of the 
activity values assigned to each allele10 (Figure 1). Within 
the CPIC guidelines, the CYP2D6 AS is then translated into a 
phenotype using the following classification system: individ-
uals with an AS of 0 are poor metabolizers (PMs), those with 
a score of 0.5 are intermediate metabolizers (IMs), those 
with a score of 1.0, 1.5, and 2.0 are normal metabolizers 
(NMs), and those with a score > 2 are ultrarapid metabolizers 
(UMs; later referred to as the “CPIC method”; Table 1).
Although the CPIC guidelines and some clinical laborato-
ries categorize an AS of 1.0 as a CYP2D6 NM, other clinical 
laboratories and the DPWG guidelines consider an AS of 
1.0 as CYP2D6 IMs6–8,11 (Table 1). Differences also exist for 
the AS value that separates NMs from UMs. Consequently, 
the different ways of inferring CYP2D6 phenotype between 
laboratories and guidelines can cause discordant CYP2D6 
phenotype assignments and, thus, lead to inconsistent 
therapeutic recommendations. To minimize confusion, it 
is important to maintain standardized CYP2D6 phenotype 
translation from genotype data. As such, the purpose of this 
project was to harmonize the systems used by the CPIC and 
DPWG and reach consensus among an international panel 
of CYP2D6 experts regarding the standardization of how to 
translate CYP2D6 genotype to phenotype.
MATERIALS AND METHODS
The Delphi survey technique is an established approach 
for seeking expert consensus on a given topic.12–14 The 
Figure 1 Process for translation of CYP2D6 genotype to phenotype. Diplotype describes the combination of two alleles (or 
haplotypes), which can involve multiple variants. Diplotype and genotype, a term that technically describes variation at a single 
nucleotide polymorphism (SNP), are often used interchangeably. Because genotype is the more commonly used term, it is used 
throughout this report. AS, activity score.
Table 1 Comparison of systems used for CYP2D6 genotype to phenotype translation
  CPIC DPWG System 1
a (n = 1) System 2 (n = 1) System 3 (n = 3) System 4 (n = 1)
AS
UM > 2 > 2.5 ≥ 3 ≥ 3 > 2 Not tested
NM to UM     2.25 < x < 3 2.5    
NM 1−2 1.5−2.5 1.75 ≤ x ≤ 2.25 2 1.5−2 1b to 2
IM to NM     1.25 < x < 1.75 1.5    
IM 0.5 0.5−1 0.75 ≤ x ≤ 1.25 1 0.5−1 0.5−1b
PM to IM     0 < x < 0.75 0.5    
PM 0 0 0 0 0 0
AS, activity score; CPIC, Clinical Pharmacogenetics Implementation Consortium; DPWG, Dutch Pharmacogenomics Working Group; IM, intermediate me-
tabolizer; NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.
AS ranges shown in gray are not reported. n refers to the number of laboratories that reported using the system.
aThis laboratory utilizes a propriety system of values to determine AS. bNM AS = 1 is a combination of a fully functional allele plus a no function allele; IM 
AS = 1 is a combination of two decreased function alleles.
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method uses a series of repeated structured question-
naires or “rounds.” Each round provides written, system-
atic refinement of expert opinion, where feedback of group 
opinion is provided after each round.15 Delphi survey tech-
nique guidelines proposed by Hasson et  al.16 were con-
sulted in the design of the project. The method used is this 
study is often referred to as a “modified-Delphi” as a major 
modification to the Delphi technique consists of beginning 
the process with a set of carefully selected options vs. an 
open-ended questionnaire.
For the Delphi method used (Figure 2), CYP2D6 expert 
members of the CPIC and DPWG were solicited by email 
invitation, as well as other international investigators with 
published expertise in CYP2D6 PGx. In addition, experts 
were solicited by posting a description of the project on the 
PharmGKB and CPIC websites.
Experts were invited to participate in a series of surveys 
using an internet-based survey tool (SurveyMonkey, Palo 
Alto, CA; http://www.surve ymonk ey.com), supplemented 
with multiple live webinars that were used to explain the 
survey and solicit feedback. The webinars were designed 
to facilitate understanding of the survey to encourage com-
pletion; toward the end of the process an additional webinar 
was used to assist in developing consensus. Each survey 
also included questions regarding the expert’s workplace 
setting and degree of CYP2D6 expertise (i.e., role in clinical 
PGx, time devoted to CYP2D6). Responses were included in 
the analysis if the respondent provided their name and con-
tact information, which were necessary to enable follow-up 
with the respondent for the subsequent round (but not dis-
closed). Responses were tabulated as numeric counts and 
frequencies for each phase to determine whether consensus 
was reached. Consensus was defined as 70% of experts 
agreeing; this level of agreement has been considered ap-
propriate in previous Delphi studies.17–19
Phase 0: Assessment
The objective of the assessment phase was to define 
areas of discordance among assignments of CYP2D6 
phenotype based on genotype. The Genetic Testing 
Registry20 was queried for laboratories performing clin-
ical CYP2D6 genetic testing, and emails requesting par-
ticipation in a survey were sent to each laboratory. The 
survey consisted of 16 questions regarding CYP2D6 
genotype interpretation, including questions regarding 
current methods used to translate CYP2D6 genotype to 
phenotype (see ref. 21 for the laboratory survey ques-
tions). Clinical practice guidelines (CPIC and DPWG) were 
evaluated for systems used to translate genotype to phe-
notype. References used in the evidence tables of the 
CPIC guidelines and additional literature were evaluated 
for differences in AS between 0.5 vs. 1 and 1 vs. 2, and 
consequences of CYP2D6*10-containing genotypes on 
AS assignment. Results were presented to the CYP2D6 
experts on the first conference call.
Phase I: Development
The objective of the development phase was to determine 
CYP2D6 genotype to phenotype translation options for 
evaluation and assess initial expert opinions on current sys-
tems being used by clinical laboratories and available PGx 
guidelines. Given that the discordance between genotype 
to phenotype translation is mostly related to the AS of 0.5, 
1, and 2 and disagreements regarding the activity value as-
signed to CYP2D6*10, the first expert conference call pro-
vided examples of pharmacokinetic studies with AS data 
Figure 2 Modified Delphi process. aComments from each round were made available to all experts and discussed on conference 
calls. AS, activity score.
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and additional studies comparing CYP2D6*10 activity (see 
ref. 21 for this spreadsheet). Experts were required to either 
attend the live conference call or to listen to the recorded 
version and asked to provide feedback and additional ref-
erences if warranted.
Phase II: Prioritization
The expert opinions discussed in the development phase 
were used to inform the prioritization phase with the final 
objective to select a genotype to phenotype translation 
system to which at least 70% of the experts agreed upon. 
Survey 1 asked specifically if experts thought there was a 
clinically significant difference between AS of 1 vs. 2 and 
0.5 vs. 1, and if there was a rationale to use a lower activity 
value for AS calculation (i.e., “downgrade” the activity value 
from 0.5 to 0.25) for some CYP2D6 alleles (e.g., CYP2D6*9, 
*10, *17, *29, and *41) to more accurately reflect activity 
relative to other CYP2D6 alleles. Survey 1 also presented 
five different systems for translating CYP2D6 genotype to 
phenotype to assess expert opinion of each system. All 
questions required expert explanation, references, and ex-
amples to support the opinion. The results from Survey 1 
were presented on a conference call and discussed, and a 
subsequent call presented two methods for assigning AS 
(i.e., AS ordinal groups vs. continuous percentage activ-
ity values). The results from Surveys 2 and 3 were used to 
prioritize one method to move into the refinement phase. 
Results including expert comments from previous surveys 
were provided with each survey.
Phases III and IV: Refinement and consensus
Based on the results from Survey 3, Surveys 4−6 were used 
to refine the details of the selected approach. Experts were 
asked a series of questions related to AS definitions for 
each CYP2D6 phenotype. A summary of comments from 
previous surveys was provided and experts were asked to 
review the comments prior to responding to subsequent 
questions.
Phase V: Validation
Once consensus was reached, results were presented on 
a member-wide CPIC call and posted to the CPIC web-
site for 2 months to allow for public comment. PharmGKB 
also blogged about the project and solicited feedback. 
Feedback was presented to the experts on a subsequent 
conference call and discussed. Survey 7 measured accep-
tance of incorporation of the feedback into the previous 
consensus system. The final survey (Survey 8) measured 




A total of 37 CYP2D6 experts participated in the project 
with 27 completing Survey 1, 28 completing Survey 2, 24 
completing Survey 3, 25 completing Survey 4, 27 complet-
ing Survey 5, 31 completing Survey 6, 23 completing Survey 
7, and 27 completing Survey 8. Not all experts participated 
in each round and some experts participated in the initial or 
early rounds but not in the later rounds or vice versa. The 
participants represented a diverse group of self-identified 
experts with varying levels of CYP2D6 expertise (Table 2) 
and an international representation: 59% were from the 
United States, 27% from Europe, and 11% from other coun-
tries (i.e., South Korea, Japan, Canada, and Australia). The 
study was facilitated by representatives from both the CPIC 
(n = 5) and the DPWG (n = 3) leadership.
Phases 0 and I: Assessment and development
Email invitations were sent to 43 clinical testing laboratories 
who reported performing CYP2D6 genotype testing to the 
Genetic Testing Registry. A total of 15 laboratories com-
pleted a survey regarding how their laboratory translated 
CYP2D6 genotype to phenotype. Of those, 47% (n = 7) re-
ported using the CPIC method for translating CYP2D6 gen-
otype to phenotype (i.e., AS of 1.0 is classified as NM). Of 
the eight laboratories (53%) not using the CPIC method (i.e., 
AS of 1.0 is classified as IM), six disclosed their CYP2D6 
genotype to phenotype translation methods (Table 1). Full 
results can be found in ref. 21. Experts participated in an 
initial conference call during which results from the labora-
tory survey were reported, evidence supporting differences 
in AS of 0.5, 1, and 2 was presented, and available infor-
mation regarding CYP2D6*10 activity was shared. Finally, 
options for a system for translating genotype to phenotype 
were discussed.
Phase II: Prioritization
In Survey 1, 93% (n = 25) of the experts agreed that there is 
a clinically significant difference between a CYP2D6 AS of 1 
and 2, and 78% (n = 21) agreed that there also is a significant 
difference between an AS of 0.5 and 1. Among the experts 
agreeing to the need to downgrade some alleles to an ac-
tivity value of 0.25 (53%; n = 14), 85% selected CYP2D6*10 
and 50% selected CYP2D6*41. Based on the first confer-
ence call discussion, Survey 1 included five potential op-
tions to move forward (Supplemental Figure S1). However, 
no method reached consensus (>  70%). Comments and 
Survey 1 results were made available to all participants and 
discussed on the second conference call. Based on feed-
back provided after the second call, a third call was held 
to discuss using a “percentage activity system” vs. the AS 
Table 2 Key demographics of CYP2D6 experts
 
No. (%)  
respondents (n = 37)
Workplace setting
 Laboratory test interpretation 3 (8)
 Nonprofit or academic hospital 14 (38)
 Reference/clinical laboratory 7 (19)
 Research or clinical institute 3 (8)
 University 10 (27)
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system (see Discussion). After receiving feedback from sev-
eral of the experts, the CPIC and the DPWG recommended 
to the experts to proceed with the use of the AS system to 
which 94% (n = 29) agreed in Survey 2. Also in Survey 2, 
42% (n = 12) preferred a system that classifies AS of 0.5 and 
1 as IMs, 38% (n = 11) preferred to create a new phenotype 
group for AS of 1, 7% (n = 2) thought both methods would be 
acceptable, and 14% (n = 4) recommended another method. 
Experts were asked to provide their rationale for their re-
sponses and Survey 2 results were discussed on a confer-
ence call. Survey 2 results can be found in ref. 22. Based on 
the conference call discussion and Survey 2 results, CPIC 
and DPWG representatives recommended to proceed with 
the use of AS and to downgrade the activity value of some 
alleles (currently limited to CYP2D6*10). Using an activity 
value of 0.25 for AS calculation to more accurately reflect 
the considerably decreased activity of CYP2D6*10 results 
in the introduction of additional AS groups. In Survey 3, the 
majority of experts (96%) agreed to create an activity value 
of 0.25 category, and 88% agreed to the assignment of AS 
0.5−1 as an IM.
Phases III and IV: Refinement and consensus
Surveys 4 and 5 were used to refine the new system dis-
cussed above. Specifically, the experts discussed how to 
integrate the new AS groups (i.e., 0.25, 0.75, 1.25, 1.75, and 
2.25) that are introduced by the addition of an activity value 
of 0.25 for AS calculations into the four phenotype catego-
ries (i.e., PM, IM, NM, and UM). As shown in Supplemental 
Table S1, Survey 5 included two options. Fourteen (52%) 
of the experts chose option 1, 11 (41%) chose option 2, 
and 2 (7%) disagreed with both options. Because the ex-
perts favored option 1 (52% vs. 41%), the CPIC and DPWG 
representatives recommended option 1 on Survey 6; this 
decision was supported by expert comments regarding 
the small contribution of an AS of 0.25 to clinically appre-
ciable activity to the overall function. Experts agreed with 
the option and consensus was reached (27 (87%) agreed, 
whereas 4 experts (13%) disagreed; Table 3).
Phase V: Validation
After 2  months of accepting public comments, 2 issues 
were revisited for consideration: (i) inclusion of a rapid me-
tabolizer (RM) phenotype group between NM and UM; and 
(ii) use of contiguous AS values to define each phenotype 
(i.e., no gaps between AS categories). After discussion on 
a conference call and Survey 6, 87% (n  =  20) of the ex-
perts rejected the introduction of an RM phenotype group, 
whereas 70% agreed to use contiguous AS ranges to de-
fine CYP2D6 phenotype based on genotype. Experts were 
also asked regarding the range for PMs: the majority (61%; 
n  =  14) favored to define PMs as having two no function 
alleles (AS = 0), 30% (n = 7) favored defining AS ≤ 0.25 as 
PMs, and 9% indicated “I do not know.” Results were dis-
cussed on a subsequent conference call on which the ex-
perts also discussed and agreed on the contiguous ranges 
for the other phenotype groups (Survey 7; 82% of the par-
ticipants (n = 22) agreeing to the final assignments shown 
in Table 3).
DISCUSSION
We engaged a diverse group of international CYP2D6 ex-
perts to establish a standardized method for translating 
CYP2D6 genotype to metabolizer phenotype. The major 
focus of this working group was to harmonize how to 
translate CYP2D6 genotype into phenotype; a secondary 
aim was to explore how currently used systems could be 
improved. This international group of experts consisted of 
representatives of academia and industry, including clini-
cal genetic testing laboratories. In addition, individuals with 
experience in implementing CYP2D6 PGx into clinical prac-
tice and electronic health records at large hospitals were 
included to assess the impact of the project on past or on-
going CYP2D6 implementation efforts. Importantly, the final 
CYP2D6 translation method presented in Table 3 will be 
incorporated into the CYP2D6 tables on www.cpicp gx.org 
and used in all new and updated CPIC and DPWG guide-
lines. We also recommend that this system be considered 












Examples of CYP2D6 diplotypes for 
consensus translation method
UM > 2 > 2.5 > 2.25 > 2.25 *1/*1xN, *1/*2xNb, *2a/*2xNb, *1x2/*9








PM 0 0 0 0 *3/*4, *4/*4, *5/*5, *5/*6
AS, activity score; CPIC, Clinical Pharmacogenetics Implementation Consortium; DPWG, Dutch Pharmacogenomics Working Group; IM, intermediate me-
tabolizer; NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.
aCYP2D6*2 is currently considered to be a normal function allele by CPIC and DPWG; however, this function assignment has been challenged32 and some 
laboratories report CYP2D6*2 function differently. Function of this allele will be reassessed as additional data become available. bN is categorical and indi-
cates the number of copy variants (e.g., *1x2, *1x3, etc).
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as standard practice across all areas of clinical PGx, includ-
ing clinical genetic testing laboratories. We also strongly en-
courage PGx researchers to use this standardized method 
to report their findings as this will greatly facilitate future 
data collection from the literature and comparison of data.
Throughout the project several issues and challenges 
were identified and discussed in detail (Table 4) as fol-
lows. (i) Lengthy discussions entailed the possibility of 
generating a new phenotype group for AS  =  0.5 as pa-
tients with genotypes consisting of one decreased and 
one nonfunctional allele seem to have lower activity com-
pared with those with genotypes giving rise to an AS of 1. 
Concerns were raised that combining AS of 0.5 and 1.0 in 
research studies may mask potentially significant differ-
ences among these AS groups because there are consid-
erably fewer subjects with an AS of 0.5. The introduction 
of a new phenotype group describing patients between 
PM and IM was, however, rejected by the CPIC and DPWG 
representatives based on the CPIC term standardization 
project, which determined that five phenotype groups are 
sufficient18; the majority of experts also rejected the intro-
duction of an additional phenotype group. (ii) A number 
of factors weighed into the decision to reclassify AS of 1 
from NM to IM. Because published studies vary on how 
subjects with an AS of 1 are grouped (NM vs. IM), it is 
difficult to compare AS of 0.5–1 vs. 2 or AS of 1 vs. 2 with 
confidence to support differences in outcomes between 
these groups. In addition, more laboratories also currently 
classify an AS of 1 as IMs and not NMs (Table 1), indi-
cating that classifying an AS of 1 as IM may be minimally 
disruptive to most research and clinical laboratories. (iii) 
Although the goal is to have a translation system that is 
agnostic to the drug used, the experts realized that cer-
tain genotypes may need recommendations that differ 
from their “drug-agnostic” phenotype group assignment. 
To address this challenge, recommendations from the 
CPIC and the DPWG can be different for certain drugs 
(see CYP2D6*10-containing genotypes in CPIC tamoxi-
fen guideline for example3), or for a particular AS group 
if warranted. In other words, a recommendation can be 
based on the AS vs. the phenotype group. Therefore, it is 
extremely important that clinical laboratories not only re-
port phenotype but also detail the patient’s genotype and 
sequence variations tested (see Bousman et al.22 for guid-
ance of how to select a PGx test).
A secondary goal of the project was to re-evaluate the 
activity values assigned to alleles with decreased function. 
Currently, a value of 0.5 bins decreased function alleles 
together regardless of the percentage activity they retain 
compared to the CYP2D6.1 (wild-type) protein product. The 
majority of values used today for AS calculation are based 
on the original report by Gaedigk et al.10 that was published 
11 years ago. The prospect of lowering the value assigned 
to CYP2D6*10, an allele that is anecdotally known to have 
Table 4 Discussion points raised by CYP2D6 experts during Delphi process
Discussion points Pros Cons
Addition of CYP2D6 RM 
phenotype
• Certain genotypes may have increased activity compared 
to NMs but less than UMs
• Addition of RM group would be in alignment with 
CYP2C19 
• Not enough evidence to differentiate between two 
increased function phenotypes (RM vs. UM) and not clini-
cally useful 
Addition of new  
phenotype group 
between IM and PM
• Combining AS of 0.5 and 1.0 in research studies may 
mask potentially significant differences among these AS 
groups
• Many studies combine AS of 0.5 and 1.0 into one pheno-
type group
• Majority of experts rejected the addition of an additional 
phenotype group
• May not be clinically useful and would be outside the 
terms developed in the term standardization project18
Changing AS of 1 from 
NM to IM
• More likely accepted by experts
• More clinical laboratories are already reporting an AS of 
1.0 as an IM
• Providing recommendations for a “normal metabolizer” 
is confusing and currently two CPIC guidelines provide 
separate recommendations for AS of 1.0
• Institutions and laboratories following the CPIC guidelines 
will need update this phenotype translation and poten-
tially re-contact previously tested patients to inform them 
of the phenotype change with any associated clinical 
recommendations
Creation of new activity 
value (0.25)
• CYP2D6*10 has been characterized as an allele conveying 
significantly decreased function across substrates
• More flexibility for assigning AS and, therefore, 
recommendations 
• Institutions and laboratories following the CPIC guidelines 
will need to update this phenotype translation and poten-
tially re-contact previously tested patients to inform them 
of the phenotype change with any associated clinical 
recommendations 
Contiguous AS scale • Can accommodate any future values of AS • No currently used activity scores fall in between the 
already listed ranges (e.g., there is no AS of 0.1) 
Percentage activity 
system
• May be more intuitive to clinicians
• May be more accurate
• Little to no data exist for the vast majority of alleles to 
discriminate activity on a scale of 0.1 (10% increments)
• Broad range of interindividual variability among subjects 
within the same genotype group
• Percent activities may still need to be translated into a 
limited number of phenotyping categories in order to fol-
low the CPIC and/or DPWG guidelines
AS, activity score; CPIC, Clinical Pharmacogenetics Implementation Consortium; DPWG, Dutch Pharmacogenetics Working Group; IM, intermediate me-
tabolizer; NM, normal metabolizer; PM, poor metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.
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“little” activity was reviewed earlier, but the authors did not 
find sufficient evidence to downgrade this allele based on 
evidence available 6  years ago.23 Since then, there was 
mounting evidence suggesting that CYP2D6*10 not only con-
sistently conveys decreased function across substrates, but 
also seems to be, on average, considerably lower compared 
with other decreased function alleles. Thus, using an activity 
value of 0.5 for AS calculation for CYP2D6*10-containing 
genotypes may overestimate the metabolic capacity of pa-
tients with CYP2D6*10/*10 or *10/no function genotypes. 
Assigning an activity value of 0.25 to the CYP2D6*10 allele 
for AS calculation will group CYP2D6*10/*10 as AS  =  0.5 
and *10/no function as AS = 0.25 (opposed to AS = 1 and 
AS = 0.5, respectively), which more precisely aligns with the 
level of reduction of enzyme activity.
Notably, there are other star (*) alleles that harbor the 
CYP2D6*10 defining variant (100C>T; rs1065852) in combi-
nation with other variants that, to the best of current knowl-
edge, do not impact function or have decreased function on 
their own (e.g., 1023C>T), which are currently classified by 
the CPIC as “decreased” function and, thus, receive a value 
of 0.5 for AS calculation (e.g., CYP2D6*49, *54, *65, and *72). 
Note that positions are provided according to the genomic 
CYP2D6 RefSeq NG_008376.3, the numbering system rec-
ommended by PharmVar.24 There are also a number of al-
leles with g.100C>T that are currently labeled as “uncertain” 
function (e.g., *37, *52, *64, *87, *94, and *95). Most experts 
recommended that these alleles should also receive an activ-
ity value of 0.25; however, concerns were raised by some of 
the experts regarding the lack of evidence (i.e., in vitro or in 
vivo studies) for most of these alleles (e.g., 100C>T in com-
bination with other SNP(s) may obliterate function, or com-
pensate for the decreased function caused by 100C>T).10,25 
Thus, other CYP2D6 alleles containing the 100C>T variant 
besides *10 will be assessed as part of future CPIC guideline 
development. At that time, functional status and values for 
AS calculations will be assigned for these alleles; other alleles 
will also be reviewed and re-assessed during this process.
It was also discussed whether genotype to phenotype 
translation should be standardized across all CYP450 en-
zymes. Currently, the AS is applied to CYP2D6 for which it 
was originally devised to accommodate a large (and grow-
ing) number of alleles with varying activity and was widely 
adopted after being published10; hence, it was a natural 
decision for the CPIC to adopt this system. The AS was 
eventually also adopted for DPYD gentoype to pheno-
type translation  to accommodate the vast number of se-
quence variants that emerged for this gene. As shown in 
Supplemental Table S2, other CYP genes have their dis-
tinct systems to translate genotype to phenotype. There was 
no consensus among the group whether this would be a de-
sirable goal because a major revision toward a CYP-wide 
system may pose a major challenge for clinical reporting and 
implementation with unclear benefits.
Feedback included the suggestion to add an RM phe-
notype group. One argument for having an RM phenotype 
group was that certain genotypes may have increased ac-
tivity compared with NMs (e.g., *1x2/*41), but less than UMs 
(e.g., *1x2/*2); it was also argued that the introduction of an 
RM group would be in alignment with CYP2C19. However, 
the experts felt that there was not enough evidence to differ-
entiate between two “increased function” phenotypes (rapid 
and ultrarapid) for CYP2D6 and, thus, these groups would 
not be clinically useful.
In 2016, the CPIC published a consensus project aimed 
to standardize terms describing allele function and phe-
notype.18 Prior to this project, various terms were used 
for allele function and phenotype, which impeded report-
ing and sharing of test results across clinical laboratories 
and electronic health records. Based on the results of this 
project, Systematized Nomenclature of Medicine-Clinical 
Terms (SNOMED-CT) and Logical Observation Identifiers 
Names and Codes (LOINC) terms were created for use in 
the electronic health record to facilitate efficient reporting 
of PGx results. Although the 2016 project did not address 
standardization of the translation of genotype to phenotype, 
PGx experts were asked whether they favor a four or five 
major category phenotype system. The majority of partici-
pants (91%; n = 48) agreed to four categories (see all survey 
results in ref. 21). The CYP2D6 experts and CPIC and DPWG 
representatives considered this result suggesting that add-
ing an additional phenotype category may not be widely ac-
cepted by the PG community.
The use of a contiguous AS scale for defining metabolizer 
phenotype was addressed at two stages during the Delphi 
process. Early in the process (call #3, Survey 2), a group of 
experts advocated for an alternative system referred to as 
the “percentage activity” system. Similar to the AS, in the 
percentage activity system, each allele is assigned a value 
on the scale of 0 (no activity) to 1 (normal activity); however, 
in the percentage activity system, values are assigned in in-
crements of 0.1 instead of 0.5 (now 0.25; Figure 3). In addi-
tion, instead of calculating the sum of the two activity values 
to calculate the AS, the values would be averaged and multi-
plied by 100 for the percentage activity system so that each 
patient’s CYP2D6 metabolic capacity is described on a per-
centage activity scale of 0% (analogous to AS = 0) to 100% 
(AS = 2.0) or higher. It was argued that the percentage activ-
ity system may be more intuitive to clinicians. Although such 
a system may ultimately be more precise, there are a number 
of hurdles. For example, the determination of activity for an 
allele is difficult as is and to discriminate activity on a scale of 
10% increments seems impossible as there are no data for 
the vast majority of alleles at this point in time. Second, there 
is a broad range of interindividual variability among subjects 
within the same genotype group10,25 and third, even if activity 
could be determined on a 10% scale, percent activities may 
still need to be translated into a limited number of phenotyp-
ing categories for feasibility of clinical implementation.
Given these challenges, the experts came to consensus 
on Survey 2 to move forward with the AS system mainly due 
to limited data for estimating percentage activity of individual 
alleles, with a general interest in future work that moves the 
field in the direction of more precise activity estimates as well 
as the prospect of developing more sophisticated dosing al-
gorithms that are based on population pharmacokinetic and 
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The second discussion of a “contiguous scale” system 
was held after the public comment period (Survey 7), after 
thresholds for each phenotype had already been agreed 
upon. Given the possibility of future allelic re-estimates or 
percentage activities, the experts defined the consensus 
scale contiguously, such that all potential values of AS have 
a consensus phenotype translation. For example, given that 
an AS = 0 is PM and an AS = 0.25 is IM, would an AS = 0.2 
be a PM or IM? Thus, the contiguous consensus scale 
(Table 3) can accommodate any future scores regardless of 
the number of groups or system used.
A central aim of this project was to continue the previously 
reported and ongoing efforts dedicated to standardizing in-
consistent components related to clinical PGx, including 
genetic testing, interpretation, recommendations, and im-
plementation.18,26–29 Importantly, we strongly encourage all 
PGx stakeholders to adopt the consent CYP2D6 translation 
system that has emerged from this project. Broad adoption 
of the proposed CYP2D6 translation system by clinical lab-
oratories as well as researchers will ultimately lead to re-
duced interlaboratory discrepancies, increased consistency 
in CYP2D6 reporting, thus more consistent test interpreta-
tion. The performance of this system will also be measurable 
over time based on the metrics from the College of American 
Pathologists Pharmacogenetic Proficiency Survey, as 
CYP2D6 genotyping/phenotyping has historically had the 
greatest interlaboratory variability among the commonly 
tested PGx genes.30 However, we acknowledge that adopt-
ing this process, if distinct from a previous reporting proto-
col, may also result in laboratory cost and effort to modify 
workflows and reconcile previously reported CYP2D6 re-
sults based on prior translation systems.
Healthcare institutions that have already implemented 
CYP2D6 genotyping using the CPIC method will be affected 
by this new system as follows: (i) patients with a CYP2D6 AS 
of 1.0 who were previously assigned an NM phenotype will 
now have to be reassigned an IM phenotype and patients 
with a CYP2D6 AS of 2.25 who were previously assigned a 
UM phenotype assigned as NM; and (ii) CYP2D6 interpre-
tive reports as well as all applicable educational materials 
pertaining to an AS of 1.0 (or 2.25) will need to be updated. 
Because the former change will necessitate substantial ef-
forts in order to back-track patients and inform them of their 
new phenotype assignment, some institutions may elect not 
to inform previously tested patients of their new re-assigned 
CYP2D6 phenotype.
The Delphi method is a powerful tool that was developed 
to build consensus among and to develop standards across 
different disciplines.12,13,15 Key risks to the validity of a 
Delphi study include overestimating the expertise of partici-
pants and attrition across the consensus rounds. Given that 
each participant had some CYP2D6 PGx expertise and 51% 
of survey respondents indicated that they spend > 26% of 
their time devoted to work related to CYP2D6, we believe 
to have had adequate CYP2D6 expertise among our sur-
vey participants. Although attrition rates were not defined a 
priori, 76% of the experts participated in Survey 7 (partici-
pation averaged 74% for Surveys 1–6) and relative to other 
Delphi panels and the recommended minimum panel size, 
our final consensus panel was relatively large (suggested 
minimum for expert panels is 10 participants), which rein-
forces the validity of our results.31 To reduce bias, especially 
the authority or reputation of specific individuals, Delphi 
panel participants are often kept anonymous throughout 
the process. Although survey creators and analysts were 
not blinded to participants, identifying information was not 
shared among survey participants. The only occasions of 
participant identification were in between surveys when 
nonblinded email invitations were sent to participants in 
conference calls and webinars during which interim results 
were discussed. Because many survey results were close, 
the CPIC and DPWG representatives discussed options for 
the next survey based on previous results and comments 
from the experts, which resulted in recommendations of lim-
ited choices to move forward. However, experts still had to 
agree to the option.
In conclusion, consensus among an international panel of 
CYP2D6 experts regarding the standardization of translat-
ing CYP2D6 genotype to phenotype was achieved. Moving 
forward, the CPIC and DPWG will use this system in their 
Figure 3 Comparison of the Clinical Pharmacogenetics Implementation Consortium method and percentage activity method for 
translating CYP2D6 genotype to phenotype. Thin lines represent different ways to translate activity score (AS) into phenotype and the 
bold lines represent the recommended CYP2D6 genotype to phenotype translation consensus system. IM, intermediate metabolizer; 
NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.
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practice guidelines. As most PGx clinical recommendations 
are based on phenotype, we anticipate that broad adoption 
of the proposed CYP2D6 genotype to phenotype translation 
framework will minimize discrepant CYP2D6 test results and 
inconsistent therapeutic recommendations.
Supporting Information. Supplementary information accompa-
nies this paper on the Clinical and Translational Science website (www.
cts-journal.com).
(Supplement to standardizing CYP2D6 genotype to phenotype transla-
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ing Group)
Supplementary Materials. Figure S1, Tables S1-S2.
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